R
Robert S. McKelvie
Researcher at University of Western Ontario
Publications - 321
Citations - 24379
Robert S. McKelvie is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 77, co-authored 312 publications receiving 21704 citations. Previous affiliations of Robert S. McKelvie include University of Guelph & Hamilton General Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
Christopher M. O'Connor,David J. Whellan,David J. Whellan,Kerry L. Lee,Steven J. Keteyian,Lawton S. Cooper,Stephen J. Ellis,Eric S. Leifer,William E. Kraus,Dalane W. Kitzman,James A. Blumenthal,David S. Rendall,Nancy Houston Miller,Jerome L. Fleg,Kevin A. Schulman,Robert S. McKelvie,Faiez Zannad,Ileana L. Piña +17 more
TL;DR: Exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization, and in key secondary clinical end points.
Journal ArticleDOI
Irbesartan in patients with heart failure and preserved ejection fraction
Barry M. Massie,Peter E. Carson,John J.V. McMurray,Michel Komajda,Robert S. McKelvie,Michael R. Zile,Susan Anderson,Mark Donovan,Erik Iverson,Christoph Staiger,Agata Ptaszynska +10 more
TL;DR: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction and there were no significant differences in the other prespecified outcomes.
Journal ArticleDOI
Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.
Robert S. McKelvie,Salim Yusuf,D. Pericak,Alvaro Avezum,R. J. Burns,Jeffrey L. Probstfield,Ross T. Tsuyuki,Michel White,Jean-Lucien Rouleau,Roberto Latini,Aldo P. Maggioni,James B. Young,Janice Pogue +12 more
TL;DR: The combination of candesartan and enalapril was more beneficial for preventing left ventricular remodeling than either candeartan or en alapril alone and was as effective, safe, and tolerable as enalAPril.
Journal ArticleDOI
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Salim Yusuf,Jackie Bosch,Gilles R. Dagenais,Jun Zhu,Denis Xavier,Lisheng Liu,Prem Pais,Patricio Lopez-Jaramillo,Lawrence A. Leiter,Antonio L. Dans,Alvaro Avezum,Leopoldo S. Piegas,Alexander Parkhomenko,Katalin Keltai,Matyas Keltai,Karen Sliwa,Ron J.G. Peters,Claes Held,Irina Chazova,Khalid Yusoff,Basil S. Lewis,Petr Jansky,Kamlesh Khunti,William D. Toff,Christopher M. Reid,Christopher M. Reid,John Varigos,Gregorio Sanchez-Vallejo,Robert S. McKelvie,Janice Pogue,Hyejung Jung,Peggy Gao,Rafael Diaz,Eva Lonn,Hope Investigators +34 more
TL;DR: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease.
Journal ArticleDOI
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Eva Lonn,Eva Lonn,Jackie Bosch,Jackie Bosch,Patricio Lopez-Jaramillo,Jun Zhu,Lisheng Liu,Prem Pais,Rafael Diaz,Denis Xavier,Karen Sliwa,Antonio L. Dans,Alvaro Avezum,Leopoldo S. Piegas,Katalin Keltai,Matyas Keltai,Irina Chazova,Ron J.G. Peters,Claes Held,Khalid Yusoff,Basil S. Lewis,Petr Jansky,Petr Jansky,Alexander Parkhomenko,Kamlesh Khunti,William D. Toff,William D. Toff,Christopher M. Reid,Christopher M. Reid,John Varigos,Lawrence A. Leiter,Dora I. Molina,Robert S. McKelvie,Robert S. McKelvie,Janice Pogue,Joanne Wilkinson,Hyejung Jung,Gilles R. Dagenais,Salim Yusuf,Salim Yusuf +39 more
TL;DR: Therapy with candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a doses of 12.5mg per day was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease.